Fig. 4
From: Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance
Additive effect of BRCA1 BRCT variants in cis. TA activity as mean percentage of wt for plasmids containing the in cis variants c.5075A>C/c.5411T>A and c.5252G>A/c.5477A>T was analysed using HEK293T and MDA-MB-231 cells with 48-h post-transfection incubation time and three to four experiments in sextuplicates. Error bars represent standard deviation (n ≥ 18)